What the trial was testing
The REFLECT enrolled 1,431 patients with rheumatoid arthritis. The study was sponsored by Pfizer and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
After two years, 72% of Crohn's patients and 64% of colitis patients were still successfully using this treatment.
Clinics and research in hepatology and gastroenterology · 2024 · NCT02925338
These findings — that were still successfully using the treatment after two years — were published in the Clinics and research in hepatology and gastroenterology and represent the headline result of the study.
Researchers tracked outcomes across 1,431 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with rheumatoid arthritis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This infusion is a biosimilar — a nearly identical copy of an established drug — and it worked well for inflammatory bowel disease. If you're already on the original version, switching to this one appears safe and effective. This treatment is FDA-approved and available now. Ask your doctor if it's right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open rheumatoid arthritis trials
Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders
The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological conditions, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), psoriatic arthritis (PsA), anxiety disorders, depressive disorders and moderate depression. Additionally, investigators will assess the program's effectiveness, as well as the challenges and facilitators involved in using an online wellness program to reduce fatigue and enhance the quality of life in patients suffering from these conditions.
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.